China’s economy grew in the 1990s and early 2000s by leveraging its low-cost labor force to become the world’s factory for cheap, low-quality goods. At the same time, Chinese consumers and corporations also viewed international brands to be of higher quality. Both of these trends are changing rapidly today, partly because of U.S.–China geopolitical issues. The trends toward deglobalization have accelerated rapidly during the current COVID-19 pandemic.
Two clear themes have emerged this year as our analyst team has had nearly 100 calls with the management teams of Chinese companies. First, there has been a rapid shift in favor of domestic brands. Second, the “Made in China 2025” initiative is creating enormous shifts in market share within the technology and healthcare sectors.
Megatrend: China’s rising domestic brands
Chinese brands are taking share from international brands across nearly every sector. Our team’s channel checks with management teams suggest that these trends accelerated in the second half of 2019 and the first half of 2020. By comparison, 85% of Chinese consumers preferred international brands to domestic brands in 2011. Today, consumers prefer domestic brands in nearly every category, according to a recent survey by McKinsey.
We see four main reasons why Chinese consumers are switching to domestic brands:
- Chinese brands have better distribution and understand their consumers better than multinationals
- Multinationals are slow to respond to trends in social media, such as TikTok and WeChat
- Domestic brands are generally 20% cheaper and have bridged the quality and product safety gap with international peers
- Amid the COVID-19 pandemic and the China–U.S. trade war, consumers who are feeling patriotic support local businesses especially
How a cosmetics company seizes opportunity
In large categories such as cosmetics and infant formula, the shift in consumer buying behavior is creating enormous growth opportunities for domestic brands. We explored this theme when we spoke to the management team of Putnam holding Proya Cosmetics in July. Proya generated just $500 million in cosmetics revenue last year. Global leader L’Oreal had $33 billion. However, we believe the Chinese firm has several competitive advantages.
First, management is focusing distribution outside of Tier 1 cities where multinationals devote all of their attention. Second, the company has brought its e-commerce presence in house, unlike the multinationals, which rely on outside vendors for this critical function. As a result, both Proya’s followers and online streaming content across key e-commerce channels are significantly over-indexed versus global peers. Tracking these data points in real time is a way to gain an edge in this undiscovered name. In spite of COVID-19, we anticipate the company’s revenue is poised to grow over 25% this year and Proya will compete in a large addressable market of $150 billion.
Megatrend: “Made in China 2025”
Made in China 2025, owing to both the trade war and the nation’s historical reliance on international technology, is one of the government’s highest priorities. The goals include increasing domestic-made content of core materials in key industries such as pharmaceuticals, aerospace, and information technology. The target is to nearly double the levels, from 40% in 2020 to 70% in 2025.
To pursue this goal, China has invested in developing human capital. China now graduates more engineers than the United States and earns more international patents. China is now producing best-in-class healthcare technology. Local governments are incentivizing hospitals to buy from domestic firms.
Specifically, medical devices are a top-10 target for China. The government is mandating 50% market share in hospitals by 2020 with this figure increasing into 2025. Mindray, a portfolio holding in Putnam Emerging Markets Equity Fund, is already a strong company with a team of 2,200 engineers and distribution covering 110,000 medical institutions. In meeting with them this past May, management indicated this policy change should drive a step change in growth.
Mindray had approximately 10% market share of the more than $1 billion ultrasound market in China. GE Healthcare and Philips healthcare dominate this industry globally with over 50% market share. However, we expect their share within China will shrink to less than 10% over the next 10 years, creating an enormous market opportunity for local players. In spite of the COVID-19 pandemic, Mindray’s revenues are poised to grow over 25% in 2020. Our fundamental research allowed us to better understand how these seismic shifts would impact the growth algorithm of the business.
Research that anticipates earnings
As deglobalization accelerates spending shifts in China, we are using insights from our meetings with company management teams to position the fund in companies we consider to be new winners.
Advisors: Read our research on why you should be careful about buying an ETF in emerging-market equities
As of September 30, 2020, Shenzhen Mindray represented 1.21% of assets in Putnam Emerging Markets Equity Fund. TikTok, WeChat, Proya Cosmetics, L’Oreal, GE Healthcare, and Philips Healthcare were not held in the fund, but may have been added to the portfolio at a later date.
More in: Equity, International